Application for Regulatory Approvals, Conferences and Presentations, and ... MarketWatch (press release) According to Gilead, the data submitted for the NDA support the use of idelalisib for patients with iNHL that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. John C. Martin, PhD, Chairman and CEO of Gilead ... |
